Hector Ye
Medical · Flushing, NYNPI 1134515422
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.8%), speaking fees and education — rather than concentrated in one kind of arrangement. AbbVie accounts for 65.7% of it on its own, with 23 other manufacturers making up the rest. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 336 payments — averaging $55.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Gilead$2K
- Phathom Pharmaceuticals, Inc.$740
- Ardelyx, Inc.$666
- Intercept Pharmaceuticals, Inc.$276
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$256
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$7,60041%
- Food & beverage$10,88859%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 115 | $12,161 |
| Gilead | 88 | $2,329 |
| Phathom Pharmaceuticals, Inc. | 16 | $740 |
| Ardelyx, Inc. | 34 | $666 |
| Intercept Pharmaceuticals, Inc. | 8 | $276 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $256 |
| Penumbra, Inc. | 3 | $245 |
| Aimmune Therapeutics, Inc. | 7 | $244 |
| Ipsen Biopharmaceuticals, Inc | 5 | $236 |
| Intra-sana Laboratories | 8 | $195 |
| Nestle Healthcare Nutrition Inc. | 9 | $176 |
| Madrigal Pharmaceuticals | 6 | $160 |
| Novo Nordisk | 1 | $125 |
| Viatris Specialty LLC | 1 | $125 |
| Vivus LLC | 6 | $112 |
| Medtronic | 1 | $108 |
| Braintree Laboratories, Inc. | 4 | $75 |
| Johnson & Johnson(2 entities) | 2 | $64 |
| Bristol Myers Squibb | 2 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| QOL Medical, LLC | 2 | $41 |
| Celltrion USA Inc. | 1 | $29 |
| Exact Sciences | 1 | $22 |
| Orphalan Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,502 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 505 | $741,907 |
| ZenpepLipase/Protease/Amylase | 101 | $192,539 |
| CreonLipase/Protease/Amylase | 109 | $136,113 |
| LinzessLinaclotide | 131 | $72,784 |
| XifaxanRifaximin | 18 | $56,579 |
| OzempicSemaglutide | 46 | $42,224 |
| DescovyEmtricitabine/Tenofov Alafenam | 16 | $34,657 |
| Mesalamine | 96 | $31,285 |
| Ursodiol | 270 | $30,176 |
| IbsrelaTenapanor Hcl | 13 | $22,025 |
| Dexlansoprazole DrDexlansoprazole | 112 | $19,334 |
| VoqueznaVonoprazan Fumarate | 17 | $10,914 |
| Tenofovir Disoproxil Fumarate | 66 | $6,028 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 12 | $5,942 |
| Entecavir | 22 | $4,692 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy, Descovy | $2,329 | $776,565521 claims |
| AbbVieCreon, Linzess | $12,161 | $208,897240 claims |
| Aimmune Therapeutics, Inc.Zenpep | $244 | $192,539101 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $256 | $60,45147 claims |
| Novo NordiskOzempic | $125 | $42,22446 claims |
| Ardelyx, Inc.Ibsrela | $666 | $22,02513 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $740 | $10,91417 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $48 | $4,59316 claims |
| Braintree Laboratories, Inc.Suflave | $75 | $1,97916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in Flushing
- Wai BongFlushing$62K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
- Gina FriesRochester$106K
- Ilse StraussSmithtown$87K
- Helen AdamsNew York$87K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.